Breast

Scientists Trained A Computer To Classify Breast Cancer Tumors

(UNC Lineberger) Nov 19, 2018 - Using technology similar to the type that powers facial and speech recognition on a smartphone, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have trained a computer to analyze breast cancer images and then classify the tumors with high accuracy.

read article

Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer

(Morningstar) Nov 20, 2018 - Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019.

read article

Syros Announces Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism at Tolerable Doses in Patients with Advanced Solid Tumors

(Morningstar) Nov 15, 2018 - Dose selected for ongoing expansion cohorts in ovarian and breast cancers supported by tolerability profile and early signs of clinical activity; data highlighted in oral plenary session at EORTC-NCI-AACR Meeting.

read article

Two Genomic Tests Identify Groups Of Patients Most Likely To Benefit From New Drugs: Latest Results From I-Spy 2 Trial

(ECCO) Nov 14, 2018 - New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalised medicine ever nearer.

read press release

AMA Urges Coverage for Added Breast Cancer Screening

(MedPage Today) Nov 13, 2018 - The decision of whether to conduct additional breast cancer screening on women with dense breasts should be made between the patient and her physician, and insurers should pay for any extra imaging if recommended, American Medical Association (AMA) delegates agreed Monday.

read article (free registration required)

FDA Grants Priority Review To Roche’s Tecentriq In Combination With Abraxane For The Initial Treatment Of People With PD-L1-positive, Metastatic Triple-negative Breast Cancer

(Roche) Nov 13, 2018 - Roche today announced the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing. The FDA is expected to make a decision on approval by 12 March 2019. A Priority Review designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease.

read corporate press release

Roche's Tecentriq Wins Fast FDA Review In Tough-to-Treat Breast Cancer

(Reuters) Nov 13, 2018 - Swiss drugmaker Roche said on Tuesday its Tecentriq medicine will get a speedy review by U.S. regulators in a tough-to-treat form of breast cancer, as it seeks to be the first company to have its immunotherapy win approval in this indication. Roche said the U.S. Food and Drug Administration (FDA) gave priority review to Tecentriq with the chemotherapy Abraxane for initial treatment of people with metastatic triple-negative breast cancer whose tumors test positive for a protein, called PD-L1, that helps them avoid immune system detection. With the accelerated review, Roche expects a decision by March 12.

read article

Novel Strategy May Reduce Breast Cancer Bone Metastasis

(Baylor College of Medicine) Nov 12, 2018 - Uncovering a novel mechanism that promotes growth of breast cancer bone metastasis has revealed a potential Achilles' heel for these cancer cells. Reported in the journal Cancer Cell, the study shows that interfering with this mechanism can reduce the risk of relapses in animal models.

read article

LexisNexis Risk Solutions Identifies Breast Cancer Treatment Facilities in the U.S. with the Highest Patient Populations

(LexisNexis) Nov 12, 2018 - California, Florida and New York have highest volumes of patients with breast cancer diagnoses.

read corporate press release

Infinity Reports Clinical and Translational Data from Expansion Cohorts of MARIO‑1 Phase 1b Study of IPI-549 in Combination with Opdivo® (nivolumab) at SITC's 33rd Annual Meeting

(The Business Journals) Nov 10, 2018 - Infinity Pharmaceuticals, Inc. announced that data to be presented today at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrated preliminary evidence that IPI-549 in combination with Opdivo® (nivolumab) is clinically active in indications not expected to respond to Opdivo alone.

read article

Breast Screening Linked To 60 Per Cent Lower Risk Of Breast Cancer Death In First 10 Years

(QMUL [UK]) Nov 9, 2018 - Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

read article

OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial

(TheStreet) Nov 7, 2018 - OncoSec Medical Incorporated today announced that the first patient has been treated in KEYNOTE-890, a Phase 2 clinical trial for the treatment of late-stage triple negative breast cancer (TNBC) with TAVO™ (intratumoral plasma encoded IL-12, or tavokinogene telseplasmid, plus electroporation) in combination with Merck's KEYTRUDA® (pembrolizumab).

read article

Morning People Are Less Likely To Develop Breast Cancer, UK Study Suggests

(USA Today) Nov 6, 2018 - Women who wake up early have a lower risk of developing breast cancer, according to researchers in the United Kingdom.

read article

Novartis Data at ASH and SABCS Show Strength Of Pipeline And Portfolio In Hematology And Oncology

(Markets Insider) Nov 2, 2018 - Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer.

read article

A Prognostic Model May Predict Survival In African-American Women With Breast Cancer

(AACR) Nov 2, 2018 - A prognostic model developed using a machine learning approach could identify African-American breast cancer patients with increased risk of death.

read press release

Coverage of Hormonal Breast Cancer Therapies Increased In States That Expanded Medicaid

(AACR) Nov 2, 2018 - An evaluation of breast cancer patients enrolled in Medicaid showed that states that expanded Medicaid during 2011 to 2017 had a 27 percent increase in prescriptions for hormonal therapy medications compared to states that did not expand Medicaid during the same period.

read press release

Women Carrying Rare Breast Cancer Variants Are More Likely to Develop Interval Breast Cancers

(AACR) Nov 1, 2018 - While the presence of common breast cancer mutations was indicative of increased breast cancer risk, the presence of certain rare mutations was indicative of increased risk from interval breast cancers and death, according to results published in Cancer Research, a journal of the American Association for Cancer Research.

read press release

Metastatic Breast Cancer Research Takes The Stage

(Fred Hutch News Service) Oct 31, 2018 - Advocates, oncologists and researchers share findings, resources and reasons for hope at third annual NW Mets Conference.

read article

Researchers Develop Test To Help Patients With Early Breast Treatment

(UC Academic Health Center) Oct 29, 2018 - Researchers at the University of Cincinnati (UC) are investigating a molecular diagnostic test to determine whether, after biopsy, someone is at high or low risk for actually developing malignant breast cancer.

read press release

Cancer Can Use Brute Force To Push Its Way Around The Body

(University College London [UK]) Oct 29, 2018 - Breast cancer cells hit blood vessel walls with up to 200 times the mechanical force exerted by normal healthy cells, finds a new UCL study.

read article
Next Page